In summary, we have described the use of NGS coupled with protein structural analysis to identify apparently disease‐causing variants in POLRMT and shown several different clinical presentations associated with these variants, highlighting the wide clinical and genetic spectrum of POLRMT‐related mitochondrial disease. This evidence concerns the gene POLRMT and mitochondrial disease.